Intraperitoneal oxidative stress in rabbits with papillomavirus-associated head and neck cancer induces tumoricidal immune response that is adoptively transferable

Annette Rossmann, Robert Mandic, Jochen Heinis, et al.

Clin Cancer Res  Published OnlineFirst June 18, 2014.
Intraperitoneal oxidative stress in rabbits with papillomavirus-associated head and neck cancer induces tumoricidal immune response that is adoptively transferable

Annette Rossmann1,2, Robert Mandic2, Jochen Heinis3, Helmut Höffken3, Oliver Küssner3, Ralf Kinscherf4, Eberhard Weihe1, Michael Bette1

1Department of Molecular Neuroscience, Institute of Anatomy and Cell Biology, Philipps University, Robert-Koch-Str. 8, 35037 Marburg, Germany. 2Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Giessen and Marburg, Campus Marburg, Baldingerstr., 35033 Marburg, Germany. 3Department of Nuclear Medicine, University Hospital Giessen and Marburg, Campus Marburg, Baldingerstr., 35033 Marburg, Germany. 4Department of Medical Cell Biology, Institute of Anatomy and Cell Biology, Philipps University, Robert-Koch-Str. 8, 35037 Marburg

Running title: O3/O2-Pneumoperitoneum induced tumoricidal immunity

Keywords: Adoptive cell transfer, cancer therapy, HNSCC, immune surveillance, tumor infiltrating lymphocytes

Financial support: This research was funded in part by the Wirtschafts- und Infrastrukturbank Hessen.

Address correspondence to: Michael Bette, Department of Molecular Neuroscience, Institute of Anatomy and Cell Biology, Philipps University, Robert-Koch-Str. 8, 35037 Marburg, Germany Tel: +49-6421-2866780, Fax: +49-6421-2868965, e-mail: bette@staff.uni-marburg.de

Disclosure: No potential conflicts of interest were disclosed by the authors

Word count of the running text (including translational relevance and abstract): 4942

Total number of figures and tables: 6
Translational relevance

The observed regression of the rabbit auricular VX2 carcinoma, a model system for human head and neck cancer, after application of intraperitoneal oxidative stress, suggested a role of the immune system in tumor clearance. Here, we demonstrate this effect to be dependent on immune cells, since the number of tumor infiltrating lymphocytes and expression of immune relevant genes significantly rose in remitting tumor tissues. Furthermore, adoptive transfer of peripheral blood leukocytes, derived from the same animals, could induce tumor regression in untreated animals with continuously growing tumors. Since the investigated VX2 carcinoma is papillomavirus associated, studying the observed tumoricidal immune response in this model system carries great promise in identifying the mechanisms underlying the immune escape of HPV positive human head and neck cancers, thereby paving the way for new therapeutic approaches.
Abstract

**Purpose:** How tumors evade or suppress immune surveillance is a key question in cancer research and overcoming immune escape is a major goal for lengthening remission after cancer treatment. Here, we used the papillomavirus-associated rabbit auricular VX2 carcinoma, a model for studying human head and neck cancer, to reveal the mechanisms underlying the antitumorigenic effects of intraperitoneal oxidative stress following O₃/O₂-pneumoperitoneum (O₃/O₂-PP) treatment.

**Experimental design:** Solid auricular VX2 tumors were induced in immune competent adult New Zealand White rabbits. Animals were O₃/O₂-PP or sham treated followed by tumor ablation after reaching no-go criteria. CD3⁺ tumor infiltrating lymphocytes (TILs) were evaluated by immunohistochemistry and expression levels of 84 immune response genes were measured by quantitative real time PCR. Adoptive transfer of peripheral blood leukocytes (PBLs), derived from animals with tumor regression, into control animals with progressing tumors, was implemented to functionally assess acquired tumor resistance.

**Results:** Auricular VX2 tumors regressing after O₃/O₂-PP treatment exhibited increased levels of CD3⁺ TILs, enhanced expression of genes encoding receptors involved in pattern recognition, molecules required for antigen presentation and T cell activation, as well as inflammatory mediators. Adoptive cell transfer of PBLs from donor rabbits with regressing tumors to recipient rabbits with newly implanted VX2 carcinoma resulted in acquired tumor resistance of the host and tumor regression.

**Conclusion:** Intraperitoneal oxidative stress effectively converts the immune response against the papillomavirus-associated rabbit VX2 carcinoma from tumor permissive to tumoricidal and leads to a sustainable adoptively transferable oncolytic immune response.
Introduction

Treatment of cancer is one of the major challenges in medical care. Despite progress in surgery, radiotherapy, and chemotherapy, the prognosis for surviving aggressive cancer is often poor. Immunotherapies represent effective approaches to combat cancer by mobilizing components of the immune system for tumor destruction. For this, recombinant cytokines or monoclonal antibodies (mAbs) targeting tumor-specific antigens (TSAs), and their receptors or ligands were all found to exert anti-tumoral effects. Vaccination against TSAs is used as a therapeutic approach in the clinic (reviewed in (1)). To design novel therapeutic interventions that stimulate tumoricidal immune responses more effectively, the specific hallmarks of cancer have to be taken into account (2). Thus, solid tumors consist of relatively few neoplastic cells (cancer stem cells, CSC), and numerous distinct cell types and subtypes within the associated stroma that collectively facilitate tumor growth and progression. A recently added hallmark of tumor pathogenesis is the deregulation of cellular energetics due to genomic instability and the active immune evasion of cancer cells enabled by tumor-mediated inflammation (2), described as cancer immunoediting (3). However, tumor associated inflammation not only initiates and supports tumor development, but can also produce anti-tumorigenic immune responses leading to tumor regression. A meta-analysis of 52 human cancer studies with various tumor entities revealed that the dominance of tumor infiltrating lymphocytes (TILs), basically CD3+ and CD8+ T cells, is associated with significantly increased survival (4).

Recruitment of the body’s immune response by precisely targeted interventions, encompassing anti-cancer vaccines (5), allogenic hematopoietic stem cell transplantation (6), and adoptive cell transfer (ACT) of ex vivo stimulated TILs offers new strategic avenues for cancer treatment (7). However, ACT is limited by the number of TILs present in tumor biopsies or by the lack of accessibility of surgical/bioptic material.

For head and neck squamous cell carcinomas (HNSCCs) an insufficient amount of bioptic tumor material often limits the use of cell based immunotherapies such as ACT, although immunotherapies are increasingly found to be effective in the treatment of HNSCCs (8). The auricular VX2 carcinoma-bearing New Zealand White (NZW) rabbit represents a generally accepted animal model, exhibiting similar growth features as observed in HNSCCs (9, 10). Similarly as the human papillomavirus-related HNSCCs, the VX2 tumor is associated with the Shope cottontail rabbit
papillomavirus (CRPV) (11, 12). Moreover, the sensitivity of VX2 tumors to local interleukin (IL)-2 therapies (13) qualifies this animal model as appropriate to test immunotherapeutic approaches.

We have recently shown that a strong oxidative stimulus generated by therapeutic insufflation of medical ozone/oxygen (O₃/O₂) gas mixture into the peritoneum (O₃/O₂-pneumoperitoneum, O₃/O₂-PP) at an advanced stage of VX2 tumor growth induced tumor eradication and the acquisition of tumor tolerance (14). The underlying cellular and molecular mechanisms of this high oxidative stress-induced tumoricidal immune response, however, are not known. Here, we analyzed the gene expression profile of mediators of the innate and adaptive immune system within the VX2 tumor tissue at an advanced stage of regression. We demonstrate that the O₃/O₂-PP-induced tumoricidal effect includes acquired VX2 tumor resistance which is adoptively transferable by PBLs from animals that had been cleared of the tumor after O₃/O₂-PP therapy. The data support current concepts of immune based cancer therapies.

Material and Methods
The animal experiments were approved by the regional board Giessen, Germany (V54-19c20-15(1) MR,Nr.34/2011) according to the German Animal Protection Law.

Animals
Overall, 40 adult Iffa Credo New Zealand White (NZW) rabbits (Charles River WIGA, Germany) in a BW range from 2.0 to 3.0 kg were used; 8 of them as donors of the VX2 cell suspension necessary for the induction of auricular tumors. Rabbits were kept in individual steel cages under standardized air conditioning at 20-22 °C, 50-60% humidity at a 12 h artificial day/night rhythm and had access to food and water ad libitum. Animals could acclimatize for at least 7 days in the hutch before the experimental procedure was started. Signs of distress, pain or cachexia - defined as weight loss above 20% - were criteria for euthanasia throughout the study.

Experimental design
The study consisted of two consecutive experimental phases. In the first phase (O₃/O₂-PP therapy, Fig. 1A), a solid auricular VX2 tumor was induced in n=20 animals. The tumor size was measured daily with a digital caliper and therapeutic intervention was started when the volume of the tumor had increased above 2,500
As the VX2 tumors reached this starting volume, animals were assigned in alternating order to one of the two experimental groups: i) animals receiving an O₃/O₂-PP therapy (n=10) and, ii) sham treated animals receiving anesthesia and a peritoneal puncture but no gas insufflation (n=8). Animals were classified as cured when the tumor decreased to <25% of its maximal volume, or classified as incurably sick when the volume increased above 6,000 mm³. These no-go criteria were based on our own initial observations that tumor decrease or increase to these limits resulted in tumor disappearance, or death within the following two months due to progressive growth or primary and/or secondary tumors. Once an auricular VX2 tumor had reached one of the no-go criteria it was surgically ablated and the animal was further observed for the development of possible metastases until day 90. At this time point the second experimental phase (adoptive cell transfer) started (Fig. 5A).

**Tumor transplantation / therapeutic approach**

VX2 tumor cells from frozen stocks were propagated by repeated *i.m.* passage within the quadriceps muscles of NZW rabbits. After 3 consecutive passages VX2 tumor cell suspensions were generated from fragmented tumor tissues and used for induction of auricular VX2 tumors as described (9). Tumor volume was measured daily and growth was allowed until the solid auricular tumor had reached a volume of >2,500 mm³. At this stage a daily therapeutic treatment with O₃/O₂ gas mixture insufflated into the peritoneal cavity (O₃/O₂-PP) or sham treatment (puncture only) were performed as described elsewhere (14).

**Surgical ablation of the tumor**

Once the no-go criteria defined by the size of the VX2 tumor was reached, the animal was sedated by Robinul® (0.1 ml/kg BW, Riemser Arzneimittel AG, Germany) (*s.c.*) and anesthetized by a mixture of Rompun® (5 mg/kg BW, Bayer Vital GmbH, Germany) / Ketavet® (70 mg/kg BW, Pharmacia GmbH, Germany) (*i.m.*). Suprarenin® (1 mg/ml, Sanofi Aventis, Germany) was *s.c.* injected peritumoral, the auricular artery was ligated proximal to the tumor and the complete tumor removed off from the adventitia (Fig. 2B and C). The wound was subsequently bandaged under compression. Compresses were changed daily until the bleeding completely stopped. Analgesic treatment with Temgesic® (Essex Pharma, Germany) (*s.c.*) was maintained for at least two days, dependent on the stage of wound healing.
**Blood parameters**

Arterial blood samples from the auricular artery of the left tumor free ear were taken prior to inoculation of the VX2 tumor cell suspension (base value) and, shortly before the first and directly after the last treatment within the five day period of O₃/O₂-PP or sham treatment. For hematological investigations, an autoanalyzer (Vet abc™ Animal Blood Counter, ABX Diagnostics, Germany) was carefully adjusted and validated for the analysis of rabbit blood. Data were expressed as mean values ± SEM.

**PET-CT**

Rabbits were anaesthetized by Robinul® plus Ketavet® as described and 0.14 mCi/kg BW radioactive labeled FDG (2-[18F]-fluoro-2-deoxy-D-glucose) diluted in 1 ml physiological saline solution was injected into the anterior vein of the ear contralateral to the tumor. A combined PET-CT analysis of the head and thorax was performed 30 min after FDG-injection using an integrated PET-CT device (Biograph 6 Truepoint PET/CT, Siemens Healthcare, Knoxville, TN). The PET-CT scans, data reconstruction, and analysis were performed according to previously described protocols (15).

**Adoptive PBL transfer**

Animals from experimental phase one were used as donors of PBLs at day 90 after VX2 tumor implantation. Blood from the lateral auricular vein was taken and PBLs were isolated by lysis of erythrocytes. For lysis, 3 ml of EDTA-blood was incubated at room temperature for 10 min in 90 ml of lysis buffer (1.55 M NH₄Cl, 100 mM KHCO₃, 10 mM EDTA), after spinning down the cell pellets were washed twice in Ca⁺⁺/Mg⁺⁺-free PBS. For each transfer 5*10⁶ cells in 1 ml of a physiological NaCl-solution were injected into the lateral auricular vein of the left ear. PBLs from i) 3 individual animals with tumor regression as a consequence of the O₃/O₂-PP therapy and, ii) 3 individual animals which exhibited progressive metastasizing tumor growth due to ineffective sham treatment were transferred into two recipients per donor. In parallel, to the adoptive transfer of PBLs, VX2 tumor was induced in the contralateral ear as described (9). Body temperature of the recipients was measured before and the first two days after cell transfer using a rectal thermometer.
RT² Profiler™ PCR Array

Information regarding the expression level of genes corresponding to the rabbit innate and adaptive immune system was assessed by the RT² Profiler™ PCR Array (PANZ-052ZA-24 for rabbit; SABiosciences, Germany) using probes of isolated total RNA from n=6 solid tumors under remission (induced by O₃/O₂-PP) and n=6 tumors under progression (unaffected by sham treatment). For each tumor sample, one 96-well RT² Profiler™ PCR Array plate containing 84 target genes and 5 independent housekeeping genes was used. Total RNA was isolated using the RNeasy Mini kit (Qiagen, Germany) and integrity, purity, and yield was analyzed with the Experion automated electrophoresis system (Bio-Rad Laboratories, Germany). Single strand cDNA from 0.5 μg total RNA was synthesized using the RT² first strand kit and real time PCR (ABI PRISM 7900HT System; Applied Biosystems, Darmstadt, Germany) was performed according to the instructions in the RT² Profiler™ PCR Array manual. The Ct values of each of the 84 target genes of a given plate were normalized with the average Ct values of the 5 independent housekeeping genes included on the same assay plate. Mean values of fold changes in mRNA levels derived from solid tumors under remission compared with mRNA expression levels of tumors under progression were calculated.

Immunohistochemistry and quantitative image analysis

Formalin fixated VX2 tumor tissue slices (7 μm thick) were immunostained with a mouse specific anti-CD3 antibody (Biozol, Germany, diluted 1:1,000) as described (16). To enhance the staining signals, the Tyramide Signal Amplification (TSA™) system (PerkinElmer, Germany) was used according to the manufactures protocol. Quantitative image analysis of immunostained CD3⁺ T cells was performed using an Olympus AX70 microscope (Olympus Optical, Germany) including a SPOT RT Slider Camera (Diagnostic Instruments Inc., Seoul, Korea) and the MCID Image system (Imaging Research Inc., St. Catherines, Ontario, Canada). The border of staining intensity for positive signals was defined and the number of CD3⁺ spots was automatically counted. Staining signals with a size of <10 pixel were excluded as false positive events. At least 10 tumor sections of each tumor, immunostained for CD3, were digitized, depending on the size of the tumor (small for tumors under remission). Data were calculated as number of CD3⁺ T cells per square millimeter solid VX2 tumor tissue.
Statistics

In all analyses a p value <0.05 was considered as significant. For calculation of statistic differences in mRNA expression levels measured by the RT² Profiler™ PCR Array, a paired t test was performed by using the free RT² Profiler™ PCR Array Data Analysis software provided by the manufacturer (http://www.sabiosciences.com/pcrarraydataanalysis.php). In all other cases the GraphPad Prism Software 4.0 (GraphPad Software, La Jolla, CA) was used. If a given mRNA quantified by the RT² Profiler™ PCR Array was induced only in one experimental group, a nonparametric two-tailed Mann Whitney Test of the ΔΔct values was performed. The logrank test was used for comparison of progression/regression rates between both experimental groups. To synchronize the course of tumor growth, the time point when the primary tumor reached 2,500 mm³ in size was set to day zero. The day of the final outcome was defined as the day a tumor had reached the no-go criteria for regression or progression. The unpaired two-tailed t-test with Welch's correction was used for comparison of changes in blood parameters directly before and after therapeutic intervention and for changes in the number of CD3+ T cells detected within the tumor tissue.

Results

O₃/O₂-PP therapy eradicates solid VX2 tumors at a high success rate.

In the first experimental phase (O₃/O₂-PP therapy, experimental design is shown in Fig. 1A), VX2 tumor cell suspension was injected s.c. in 20 NZW rabbits which resulted in the development of a solid auricular VX2 tumor in 18 animals (tumor take-rate 90%) reaching a volume of 2,500 mm³ at day 13±2 (Fig. 1B and C). At this stage, animals received either the O₃/O₂-PP therapy or underwent sham treatment. Tumor volume further increased until around day 18, independently of the treatment. Thereafter, in 7 out of 10 animals (70%) which had received O₃/O₂-PP treatment the tumor continuously decreased (Fig. 1B), whereas in 6 out of 8 sham treated animals (75%) tumor size further increased above a critical volume of 6,000 mm³ (Fig. 1C). At this stage, tumors strongly ulcerate, which finally leads to death. Kaplan–Meier analysis revealed that the time to tumor regression (TTR) probability was significantly higher after O₃/O₂-PP therapy in comparison with sham treated animals (Fig. 1D). Accordingly, sham treatment had no impact on tumor development. The time to tumor progression (TTP) probability was significantly higher in the sham compared
with the \(O_3/O_2\)-PP treated group (Fig. 1E). Nevertheless, spontaneous remission occurred in 2 out of 8 sham treated animals (25%) albeit the period required for spontaneous tumor clearance was longer (19±2 days) in comparison with the time needed for \(O_3/O_2\)-PP-induced remission (14±2 days).

According to the typical course of HNSCC disease, all animals exhibiting progression of the primary tumor (\(n=3\) for \(O_3/O_2\)-PP treatment and \(n=6\) for sham treatment) demonstrated metastases in the ipsilateral lymph nodes (Fig. 2A). Nearly all animals which had cleared the primary tumor were free of lymph node metastases (\(n=6\) for \(O_3/O_2\)-PP treatment and \(n=2\) for sham treatment) except 1 animal from the \(O_3/O_2\)-PP group (Fig. 2A). Presence of metastases in cervical lymph nodes was diagnosed by PET-CT (Fig. 2D-I) in the living animal (Fig. 2 E-K) and by macroscopic (Fig. 2B) and histological postmortem examination (Fig. 2 L and M). In addition, within the 90 days observation period, the therapeutic effect of \(O_3/O_2\)-PP suggests protection against metastases.

**\(O_3/O_2\)-PP-induced tumor clearance is associated with an increase in WBCs and TILs**

To test the hypothesis that leukocytes are involved in the \(O_3/O_2\)-PP induced tumor defense, we analyzed major blood parameters before and directly after the last therapeutic intervention. The hemogram revealed a significant increase in white blood cells (WBCs) exclusively in \(O_3/O_2\)-PP treated animals (Fig. 3A), while other blood values remained within the physiological range (Supplementary Table S1). Quantitative image analysis exhibited a significant 5-fold increase in the number of CD3\(^+\) T lymphocytes in the tissue of tumors which underwent remission as compared to the tissue of tumors which exhibited progression (Fig. 2B-D). This suggests that TILs are causally involved in VX2 tumor clearance.

**Immune signature in tumors under \(O_3/O_2\)-PP-induced remission**

A multiplex qPCR Assay representing 84 different inflammation relevant markers was used to decipher immune reactions occurring in tumors remitting after \(O_3/O_2\)-PP-treatment. The entire list of all components can be found as Supplementary Table S2.

Tumor remission is associated with enhanced transcription of immune-related genes in the respective tumor tissue, which include pattern recognition receptors (PRRs) (Fig. 4A), elements functionally involved in signal transduction cascades (Fig. 4B)
and factors known to modulate, regulate or support ongoing immune responses by different mechanisms (Fig. 4C). This could include the generation of a positive chemoattractant milieu by the enhanced expression of complement factor C3, the chemokine (C-C motif) ligands 2 and 3 and the local expression of proinflammatory cytokines, potentially boosting the immune response. Down-regulation of the local expression of cyclooxygenase 2 (COX-2), an enzyme required for producing immune-suppressive prostaglandins might contribute to an increase in local immune response.

The involvement of the adaptive immune system in O₃/O₂-PP-induced tumor defense is indicated by an enhanced expression of receptors and ligands involved in antigen presentation and induction of T cell immune responses (Fig. 4D). The MHC class I-related protein CD1d, which specifically presents lipid antigens to T cells, was expressed at about 8-fold higher levels in remitting tumors. In addition, the T cell co-receptor CD4, necessary for MHC class II-dependent antigen detection and the costimulatory binding couples CD80/CD28, CD86/CD28, and CD40/CD154 (CD40 ligand) were found elevated 2- to 6-fold (Fig. 4D). Thus, enhanced local antigen presentation seems to take place and might contribute to the tumoricidal immune response.

Differentiation of TILs into the T cell subpopulations T1, T2, Tregs and, TH17 according to the accepted classification, revealed a role of T1 and T2 cells in tumor regression (Fig. 4E). Expression of genes encoding receptors characteristic for T1 cells and IFNγ were significantly enhanced and the expression of the T2 associated cytokines IL-4, IL-5, and IL-10 were induced only in animals with tumor remission (Fig. 4E). Although markers for Tregs (CCR8) and TH17 cells (CCR6) were not significantly enhanced in tumors under remission, the transcription factor FOXP3 was significantly elevated in tumors under remission, suggesting involvement of Tregs and/or TH17 cells in tumor clearance. RORC expression was slightly reduced in remitting tumor tissues and IL-17a was always absent (Fig. 4E).

**O₃/O₂-PP therapy induced acquired tumor resistance that can be transferred by ACT**

PBLs isolated from donor rabbits which either had been cleared of the tumor in response to the O₃/O₂-PP therapy (assumed to be “tumoricidal” PBLs), or from sham treated rabbits suffering from progressive tumor growth (assumed to be “non-
tumoricidal” PBLs), were transferred to recipient rabbits in which an auricular VX2 tumor was induced in parallel (experimental design is shown in Fig. 5A). No signs pointing to rejection such as change in body temperature (Fig. 5B) or sickness behavior were observed in the recipient rabbits. All recipients developed an auricular VX2 tumor continuously growing until day 17 p.i., irrespectively of the source of PBLs transferred (Fig. 5C). In the subsequent period, 3 out of 5 animals (60%), which had received ACT of “tumoricidal” PBLs, were able to clear the tumor (Fig. 5C). In contrast, none of the animals (6/6, 100%), which received “non-tumoricidal” PBLs showed tumor clearance (Fig. 5C). The probability of tumor progression or regression significantly differed between the two recipient groups (Fig. 5D and E). This confirmed our hypothesis, that cells of the immune system are functionally involved in the tumoricidal impact of the O₃/O₂-PP therapy.

Discussion

At the time of diagnosis tumors have often developed to a macroscopically visible and clinically critical size. At this time, defense mechanisms of the body against tumor cells have failed, probably due to immune evasion of the tumor cells (17). In the worst case, tumor cells reprogram cells of the tumor microenvironment (TME) including immune cells to promote growth and vascularization of the tumor (18, 19). On the other hand, immune based therapies have proven to be powerful weapons against cancer once the immune system is reprogrammed to detect the neoplastic cells. Novel ACT treatment paradigms showing that sensitization and activation of anti-tumorigenic leukocytes derived from the patient’s own immune system can be used as a therapeutic tool for cancer treatment (7, 20).

In this study, we were able to trigger such a tumoricidal immune response after application of a repetitive highly oxidative stimulus by insufflation of a medical O₃/O₂ gas mixture into the peritoneal cavity. O₃/O₂-PP treatment led to resistance against the tumor which was transferable by ACT. In contrast to the ACT of ex vivo stimulated TILs however, the O₃/O₂-PP approach does not require surgical preparation of tumor cells and TILs from solid tumors, which are often difficult to obtain.

We observed that O₃/O₂-PP treatment led to a significant increase of peripheral WBCs and CD3⁺ TILs in the VX2 tumor tissue, compared to sham treated tumors. If the increase in WBCs depends on the O₃/O₂-PP treatment alone, or might reflect the
beginning of an expansion of anti-tumorigenic leukocytes, is unknown. The increase of CD3+ TILs is in accordance with clinical studies showing that high abundance of TILs in tumors is often associated with increased survival of cancer patients (4, 21-23), whereas low density of intra- and peritumoral CD3+ CD4+ and CD8+ cells is associated with increased risk of relapse as reported for squamous cell cervical cancer (24). Apparently, TILs are major players in cancer immune surveillance by virtue of their capacity to recognize, capture, and eliminate transformed cells (25, 26).

The molecular signature of immune response genes, measured in VX2 tumors remitting after O3/O2-PP treatment, indicates an enhanced activation of the innate and adaptive arms of the immune system implicating a role of activated TILs.

The up-regulation of the PRRs in remitting VX2 tumors may reflect an induction or increase in the sensitivity to detect ongoing pathological changes and might be essential for triggering the tumoricidal response. Damage-associated molecular pattern molecules (DAMPs) (27, 28) such as DNA/RNA fragments, glucose or ATP released from VX2 tumor cells by itself or from cells of the TME might function as ligands for these PRRs (29). In fact, DAMPs are often critical for tumor development. For example, pathophysiologically released ATP was described as an activator of the NOD-like receptors (NLR)P3 inflammasome, which mediates the cleavage of pro-IL-1β and pro-IL-18 to biologically active cytokines or might subsequently trigger pyroptosis (30, 31). Two central components of the inflammasome (the platform protein NLRP3 and the effector protein caspase 1 (32)) were up-regulated in remitting VX2 tumors. This might imply the formation and activation of inflammasomes within the TME and might be responsible for the increase in IL-18 gene expression (33).

The signature of enhanced PRR mRNAs might indicate an anti-tumorigenic effect of TLRs, NLRs, and RIG-I-like receptors in remitting VX2 tumors, albeit protumorigenic effects of PRRs are also known (34, 35).

Activation of PRRs leads to initiation of several signal transduction pathways resulting either in the synthesis of type I interferons (IFNs), cytokines and growth factors, or in pyroptosis of the cell (36). Consistent with the observed expression of PRRs, an increase of numerous related downstream signaling molecules and transcription factors was noted in remitting VX2 tumors. These include the essential
signal molecule MyD88 which, in relationship to TLR2, TLR4, TLR6 is known to result in mitogen-activated protein kinases and/or NF-κB dependent expression of several inflammatory cytokines (36), especially the synthesis of pro-IL-1β and pro-IL-18. Surprisingly, NF-κBIA, an inactivator of NF-κB is also enhanced in remitting VX2 tumors. However, enhanced NF-κBIA seemed unable to efficiently block NF-κB-dependent gene transcription of cytokines, because TNF-α, MIP-1α and IFNγ mRNAs were still detectable at significant levels in remitting VX2 tumors. This discrepancy might be explained by the expression of NF-κB and NF-κBIA in different cell populations within the tumor tissue.

Expression of COX-2 was decreased in the VX2 tumors under O₂/O₂-PP-induced remission. As protumorigenic effects of COX-2 derived prostaglandins such as PGE2 are related to tumor growth, angiogenesis, and inhibition of apoptosis (37), the diminished COX-2 expression in remitting tumors is likely to result in a reduction of tumor permissive factors in the tumor microenvironment. In fact, blockade of COX-2 by specific inhibitors is actually used for cancer chemotherapy (38, 39) and blockade of COX-2 by the unspecific COX-inhibitor acetylsalicylic acid gains significance (40). Further, factors involved in chemoattractants namely complement factor C3, CCL2 and, CCL3 might be causally involved in the increase of TILs in remitting VX2 tumors.

The presentation of tumor antigens in combination with costimulatory signals by APCs is essential for utilization of the adaptive arm of the immune system. The observation of enhanced expression of the binding partners CD80/CD28, CD86/CD28, CD40/CD154 (CD40L), the T helper cell specific CD4, and the MHC I related receptor CD1d in remitting VX2 tumors supports our view of a decisive role of TILs in tumor defense. In this context, it is interesting to point out that the VX2 carcinoma initially developed after Shope papillomavirus-induced transformation of normal keratinocytes (12). Similarly, about 25% of HNSCC tumors or more, dependent on their anatomical site, are associated with high-risk human papillomaviruses (HPVs) in particular the type 16 (41). The papillomavirus oncoprotein E5 is implicated in MHC-class I down regulation (42, 43) and was shown to affect MHC class II maturation in IFNγ-treated keratinocytes (44). Consistent with these reports, the VX2 carcinoma was found to express E5 mRNA at high levels (data not shown). Overexpression of E5, therefore could be related to the observed
immune escape of the VX2 tumor that was overcome by immune modulatory effects of the O\textsubscript{3}/O\textsubscript{2}-PP treatment.

Further gene expression analysis of T cell subtype specific receptors and cytokines, points to an involvement of effector T1 and T2 cells. The exact role of T\textsubscript{regs} and T\textsubscript{H}17 cells in the VX2 tumor model remains to be unraveled in studies to come. Based on the measured FOXP3 expression levels in remitting tumors a functional involvement of these regulatory cell types seems likely, although other markers relevant for the identification of these cell types were not significantly enhanced. Both cell types, T\textsubscript{regs} and T\textsubscript{H}17, have been described to exhibit pro- as well as anti-tumorigenic effects in different types of human cancers (reviewed in (45, 46)). The combined up-regulation of IL-2, IL-10, IL-18, and IFN\textsubscript{Y} suggests that an immune response driven by T\textsubscript{H}1 and cytotoxic T cells and NK cells might preponderate in remitting tumors. This is in line with data, showing that IL-10 in combination with IL-2 can increase the cytolytic activity of CD8\textsuperscript{+} T cells (47), and in combination with IL-18 the cytolytic activity of NK cells (48).

The most likely mechanism by which O\textsubscript{3}/O\textsubscript{2}-PP induces the tumoricidal response seems to be related to the stimulation of immune cells in consequence of the oxidative gas insufflated into the peritoneum. This probably includes anti-tumorigenic T cells but also resident macrophages and DCs. How the highly oxidative stimulus within the peritoneal cavity reaches and affects these leukocytes within the tumor tissue is at present unclear. In principle, two starting points of the gas are conceivable (Fig. 6). On the one hand, the radical gas could act directly on circulating immune cells (49) within the peritoneal cavity, and either activate anti-tumorigenic leukocytes, or destroy immune suppressive immune cells, e.g. suppressor T cells, which until then had blocked anti-tumorigenic cells. On the other hand, oxidation of numerous biomolecules like lipoproteins can lead to the generation of ROS and LOPs (lipid oxidation products) (50) which can function as DAMPs (51) within the peritoneum, or locally after reaching the tumor via the blood stream. In fact, ROS endogenously produced in case of cellular stress have been found to function as DAMPs and are thought to be common initiators of the NLRP3 inflammasome pathway (33, 51, 52).

Unequivocal proof that immune cells are responsible for VX2 tumor eradication has been made by adoptive transfer of isolated PBLs. The ACT of PBLs derived from
O$_3$/O$_2$-PP-treated animals, which had been able to clear the primary tumor, also led to tumor clearance in host animals with a 60% success rate. We suggest, that the adaptive immune system is crucially involved in the O$_3$/O$_2$-PP induced tumor defense and that long lasting “memory” cells against the VX2 tumor must have developed. Thus, medically implemented oxidative stress by O$_3$/O$_2$-PP is suggested as a novel therapeutic approach to induce sustainable adoptively transferable oncolytic immune responses.

Acknowledgement

The authors thank Mrs. R. Peldszus and Mrs. G. Sadowski for preparation of the VX2 tumor cell suspension and G. Schemken and Dr. M. A. Juratli for their assistance during the animal experiments. We also like to thank Dr. H. Ibelgaufts for his data base “Cope with cytokines”

References


Figures

Figure 1. Experimental design and growth kinetics of VX2 tumors. A, treatment scheme of the O₃/O₂-PP therapy and the defined no-go criteria. B, C, growth kinetics of VX2 tumors in animals of the O₃/O₂-PP and sham group. Mean values ± SEM are shown if the number of samples was >3 (filled icons). If the number was ≤3 the moving average over three days is shown by dashed lines. The gray dashed line indicates the threshold of tumor volume at which the therapeutic approach started. D, Kaplan-Meier analysis depicting the time to tumor regression (TTR) probability and (E) the time to tumor progression (TTP) probability of solid auricular VX2 tumors. Treatment of each individual animal started when the auricular VX2 tumor exceeded a volume of 2,500 mm³ and was set to day 0. The TTP or TTR probabilities were defined by the tumor volume. The TTP was reached when the tumor volume increased above 6,000 mm³ and TTR was reached when the tumor volume decreased below 25% of its maximal volume. Statistically significant changes between the O₃/O₂-PP and the sham group were calculated by the logrank test and marked with \( p < 0.05 \); numbers and percentages of tumors showing regression (B, D) or progression (C, E) are shown in brackets.

Figure 2. Metastatic spread of VX2 tumors in the rabbit. A, frequency of lymph node metastasis in animals with regressing and animals with progressing tumors. The number of animals for each therapeutic outcome and treatment is shown in brackets. Macroscopic views of (B) a submandibular sentinel lymph node harboring metastatic tumor tissue, (C) a primary auricular tumor and, (D) an ear directly after surgical ablation of the tumor. E-G, PET-CT analyses of a sham treated rabbit suffering from regional metastases at the proximal region of the ear, and the respective sentinel lymph node. H-K, PET-CT analysis of an O₃/O₂-PP-treated and tumor free rabbit. PET-CT images were 3D reconstructed and labeling intensity of \([^{18}\text{F}]-\text{FDG}\) was depicted by false colors. The dotted lines in (F) and (I) specify the level of the frontal scan reconstructions shown in (G) and (K), respectively. Note the light areas in panels E and H marked by arrows, representing the remaining thin tissue area after tumor ablation as shown in D, exemplarily. L, M, microscopic views of a Haematoxylin/Eosin stained sentinel lymph node containing VX2 tumor metastases.
**Figure 3.** Effect of O₃/O₂-PP treatment on leukocyte numbers. A, changes in the number of white blood cells (WBCs) directly before the first and after the last therapeutic intervention or sham treatment. B, numbers of CD3⁺ T cells within tumor tissues under remission or progression measured by digital image analysis of auricular VX2 tumors immunostained for CD3. Statistical differences were calculated by the two-tailed t-test with Welsh correction and marked with: *p<0.05, ***p<0.0001. Depicted are mean values ± SEM. Representative CD3-immunostained tumor sections from a VX2 tumor under remission or under progression are shown in (C) and (D), respectively. The inserts show CD3⁺ cells present in (C) and (D) at higher magnification.

**Figure 4.** Expression levels of immune relevant genes in the tumor tissue. Immunologically relevant factors were grouped according to their mode of action in (A) pattern recognition receptors, (B) signal transduction factors, (C) mediators or regulators of inflammatory responses, (D) molecules functionally involved in antigen presentation to T cells and T cell activation by essential co-stimulatory signals and, (E) T cell subpopulations identified by their specific expression pattern. Shown are mean values of fold changes in mRNA levels from solid tumors under remission (induced by O₃/O₂-PP, n=6) compared with mRNA expression levels of tumors under progression (unaffected by sham treatment, n=6). Values above 0.0 represent increased expression levels in the remitting tumor. Significant differences between tumors under regression and progression were calculated with the unpaired t-test and marked as: *p<0.05; **p<0.01; ***p<0.001; n.s. not significant, n.d. not detected. If a given factor was induced in one experimental group only, a scatter plot of ΔΔct values is depicted on the right side of the equivalent bar graphs. Grey areas in each scatter plot represent the range that was defined as negative (mRNA expression not verifiable due to a ct value >35 cycles = ΔΔct < 0.00047). In this case a nonparametric two-tailed Mann Whitney test of the ΔΔct values was used. Abbreviations in bars below the x-axes: TLR: Toll-like receptors; RLR: RIG-I-like receptors; NLR: NOD-like receptors; trans.f.: transcription factor; sup.: immune suppressive, chem.at.: chemoattractant; pro.inf.: pro-inflammatory; AP: antigen presentation; IgS: Immune globulin superfamily; TNFR: tumor necrosis factor receptor superfamily; T1, T2, T17: type 1, 2, 17 T cell; Tregs: regulatory T cell. Abbreviations of genes: C3: complement component 3; CCL2, 3: chemokine (C-C motif) ligand 2, 3; CCR4, 5, 6, 8: chemokine (C-C motif) receptor 4, 5, 6-like, 8;
CD1d, 4, 28, 40, 86, 154: cluster of differentiation CD1d, 4, 28, 40, 86, 154; C-Jun: C-jun transcription factor; COX-2: cyclooxygenase-2; CXCR3, 4: chemokine (C-X-C motif) receptor 3, 4; FOXP3: forkhead box P3; IFNγ: interferon gamma; IL-2, -4, -5, -13, -15, -17a, -18: interleukin-2, -4, -5-like, -13, -15, -17a, -18; IRAK1: interleukin 1 receptor-associated kinase 1-like; IRF1: interferon regulatory factor 1; MAPK1, 3, 8, 14: mitogen-activated protein kinase 1-like, 3-like, 8, 14; MDA-5: melanoma differentiation-associated gene 5; MyD88: myeloid differentiation primary response gene 88-like; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells 2; NF-κBIA: nuclear factor kappa-light-chain-enhancer of activated B cells inhibitor alpha; NLRP3: NLR family, pyrin domain containing 3; NOD1, 2: nucleotide-binding oligomerization domain containing 1, 2; RIG-1: retinoic acid inducible gene-I; STAT1: signal transducer and activator of transcription 1; TLR1, 2, 3, 4, 6: toll-like receptor 1-like, 2, 3, 4, 6; TNF: tumor necrosis factor; TRAF6: TNF receptor-associated factor 6; TYK2: tyrosine kinase 2-like

**Figure 5.** Tumor resistance induced by ACT of PBLs. A, experimental design of the ACT. O₃/O₂-PP treated rabbits which have been able to clear the tumor or sham treated, tumor sick rabbits, both derived from experimental phase 1, were used as donor animals for PBL transfer. B, mean body temperature ± SEM of recipient animals before and after ACT. The physiological range of body temperature of NZW rabbits is marked in gray. C, VX2 tumor size development after simultaneous VX2 tumor cell inoculation and ACT of PBLs derived from either O₃/O₂-PP treated, cured or sham treated (tumor sick) animals. Shown are the mean values ± SEM of the VX2 tumor size from all progressively growing tumors within the PBL-sham group and from remitting tumors of the PBL-O₃/O₂-PP group. The dashed line represents the moving average over three days of progressively growing tumors of the PBL-O₃/O₂-PP group. D, Kaplan-Meier analysis of the time to tumor regression (TTR) probability and (E) the time to tumor progression (TTP) probability of solid auricular VX2 tumors. Statistically significant changes between the two groups were calculated by the logrank test and marked with *p<0.05*; numbers and percentages of tumors that had reached the defined tumor volume characteristic for progression or regression are shown in brackets. Mean values ± SEM are shown.
Figure 6. Proposed model for the underlying mechanisms of the O₃/O₂-PP mediated tumoricidal immune response. Within the peritoneal cavity O₃/O₂ might i.) kill immune cells including T suppressor cells, which so far have inhibited a tumoricidal immune response or, ii.) stimulate immune cells directly (direct pathway) or via the generation of ROS and LOPs (indirect pathway). Circulation of activated immune cells and ROS and LOPs via the blood stream leads to a complex immune response within the tumor tissue under joint contribution of the innate and adaptive immune system.
Figure 1. 

(A) Tumor induction and treatment

- Tumor size: >2,500 mm³
  - O₂/O₂-PP: n=10
  - sham: n=10

- No-go criteria
  - Tumor size: >6,000 mm³
  - Progression: ><25% of its max. volume

- Blood analysis I, II, III
- Surgical ablation of the auricular tumor
- PET-CT:
  - Isolation of PBLs for adoptive cell transfer

(B) Tumor volume over time after tumor inoculation

- O₂/O₂-PP (n=7)
- Sham (n=3)

(C) Tumor volume over time after tumor inoculation

- Sham (n=6)
- Sham (n=2)

(D) TTP probability over time after treatment

- O₂/O₂-PP (7/10; 70%)
- Sham (2/8; 25%)

- * p = 0.0482

(E) TTP probability over time after treatment

- Sham (6/8; 75%)
- O₂/O₂-PP (3/10; 30%)

- * p = 0.0454
Figure 2

Figure 2 shows various images and graphs related to cancer research. The figure includes images of animal models with different stages of cancer progression and regression, along with bar graphs depicting the number of animals with lymph node metastases. The images and graphs are labeled from A to M, with each representing different aspects of the research.

A. Bar graph showing the number of animals with regression or progression of cancer.
B, C, D. Images of animal models with visible tumors and lymph node metastases.
Figure 3

(A) Changes in WBC count [10^3/mm^3] for Ozon and Sham groups.

(B) Number of CD3+ cells/mm^2 in remission and progression.

(C) Images showing microscopic sections at 50 μm scale.

(D) Images showing microscopic sections at 50 μm scale with detailed sections at 10 μm scale.
Figure 5  CCR-14-0677

A  Tumor induction: left ear
Transfer of PBLs; right ear vein
derived from:
- Ov/O2-PP treated rabbits
- sham-treated rabbits

no-go criteria
- tumor size:
  - Progression: >6000 mm³
  - Regression: < 25% of its max. volume

daily measure
tumor growth
15 37
time [day]

Euthanasia:
tumor resection

B  Body temperature (°C)

0 0.5 1
ACT
Body temperature
38.0 38.5 39.0 39.5

PBLs sham
PBLs Ov/O2-PP

C  Tumor volume [mm³]

0 1000 2000 3000 4000 5000

PBLs sham
Progression (n=6/6)
PBLs Ov/O2-PP
Progression (n=2/5)
PBLs Ov/O2-PP
Regression (n=3/5)

D  TTP probability [%]

0 20 40 60 80 100

n=11
PBLs sham
(6/6; 100%)
PBLs Ov/O2-PP
(2/5; 40.0%)

* p = 0.0158

E  TTR probability [%]

0 20 40 60 80 100

n=11
PBLs Ov/O2-PP
(3/5; 60.0%)
PBLs sham
(0/6; 0%)

* p = 0.0315
Figure 6

Direct pathway
- Stimulation of immune cells incl. T_{sup} cells
- Oxidation of biological molecules as DAMP
- Activation of immune cells

Indirect pathway
- Killing of immune cells
- ROS functioning as DAMP

Peritoneal cavity
- Circulation

Remitting tumor
- DC
- Granulocyte
- Macrophage
- CD8
- CD4
- T_{help}
- T_{cyt}
- ROS

Downloaded from clincancerres.aacrjournals.org on August 18, 2014. © 2014 American Association for Cancer Research.